tiprankstipranks
Blurbs

Maxim Group Maintains Their Buy Rating on Electrocore (ECOR)

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Electrocore (ECORResearch Report), with a price target of $1.50. The company’s shares closed last Friday at $0.60.

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 3.8% and a 36.3% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, Applied DNA Sciences, and Dermata Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Electrocore with a $1.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $1.30 and a one-year low of $0.27. Currently, Electrocore has an average volume of 256.4K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ECOR in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.

Read More on ECOR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles